Fig. 1: Identification of multiomics subtypes in Korean NSCLC patients.

a Summary of clinical information for the Korean NSCLC patient cohort. Bar plots show NSCLC histology, tumor stages, pathologic N status, and tumor recurrence status with adjuvant treatment. b Numbers of quantified proteins and PTM sites identified in global proteomic, phosphoproteomic, and acetylproteomic analyses. The number of features quantified at <30% missing values across 229 samples is represented by the yellow line. c Overview of NMF clustering. Other tumor suppressor genes consisted of CDKN2A, STK11, KEAP1, RB1, PPP2R1A, and SMARCA4. Other oncogene alterations consisted of frameshift deletions; in-frame deletion/insertion and missense mutations in KRAS, ERBB2, and PIK3CA; exon skipping in MET; and gene fusion in ALK, ROS1, and RET. Copy number loss was defined as homozygous deletion (absolute copy number <0.5). d Enrichment of the five identified NMF clusters for clinical variables. Tests indicating statistical significance (P < 0.05, two-sided Fisher’s exact test) are colored according to the odds ratio (OR). Box size indicates the proportion of the cohort characterized by a given clinical variable. e Pathway enrichment analyses of the five subtypes using GSVA and PTM-SEA. Pathways with statistical significance (FDR < 0.05, permutation) and positive enrichment scores (z-score) are represented by dots.